Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has accepted to review Regeneron Pharmaceuticals’ resubmitted biologics license application (BLA) for linvoseltamab to treat adults with relapsed/refractory (R/R) multiple myeloma (MM).
The concluded Phase I portion of the trial evaluated the therapy’s tolerability, dose-limiting toxicities, and safety. Credit: Trnava University on Unsplash.
Subscribe to our email newsletter
Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and are refractory to the last therapy line.
A decision on the approval from the US regulator for the therapy is expected on 10 July 2025.
The FDA’s BLA acceptance follows the resolution of third-party fill/finish manufacturing concerns raised by the agency in the prior BLA submission.
Regeneron’s latest application is backed by data from the multicentre, dose-escalation, and dose-expansion Phase I/II LINKER-MM1 trial in 282 subjects.
The concluded Phase I part of this trial evaluated the therapy’s tolerability, dose-limiting toxicities, and safety at nine different dose levels.
Furthermore, the Phase II dose-expansion portion, which is ongoing, is evaluating the anti-tumour activity and safety of the candidate with objective response rate as the primary endpoint.
The therapy, as a single agent as well as in conjunction with other treatments across several lines of therapy in MM, is being studied in a clinical development programme.
This includes investigating its use in earlier treatment lines, and in plasma cell precursor disorders.
An investigational BCMAxCD3 bispecific antibody, linvoseltamab is tailored to connect B-cell maturation antigen on myeloma cells with a cluster of differentiation 3 (CD3)-expressing T cells, to trigger T-cell activation and cancer cell destruction.
In the US, linvoseltamab received fast track designation from the FDA to treat R/R MM.
